Abstract:ABSTRACT Background Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. While mepolizumab’s short-term effectiveness is established, there is limited evidence on its ability to achieve long-term clinical remission. Objective To evaluate the long-term effectiveness and safety of mepolizumab, explore its potential to induce clinical and sustained remission, and identify baseline factors associated with the likelihood of achieving remission over 24 months. Methods The REMI-M is a retrospective, real-world, multicenter study that analyzed 303 severe eosinophilic asthma patients who received mepolizumab. Clinical, demographic, and safety data were collected at baseline, 3, 6, 12, and 24 months. The most commonly used definitions of clinical remission, which included no exacerbations, no oral corticosteroids (OCS) use, and good asthma control with or without assessment of lung function parameters, were adopted. Sustained remission was defined as reaching clinical remission at 12 months and maintaining it until the end of the 24-month period. Results Clinical remission rates ranged from 28.6% to 43.2% after 12 months and from 26.8% to 52.9% after 24 months, based on the different remission definitions. The proportion of patients achieving sustained remission varied between 14.6% to 29%. Factors associated with the likelihood of achieving clinical remission included the presence of aspirin-exacerbated respiratory disease, better lung function, male sex, absence of anxiety/depression, gastro-esophageal reflux disease, bronchiectasis, and reduced OCS consumption. Adverse events were infrequent. Conclusions This study demonstrates the real-world effectiveness of mepolizumab in achieving clinical remission and sustained remission in severe eosinophilic asthma over 24 months. The identification of distinct factors associated with the likelihood of achieving clinical remission emphasizes the importance of comprehensive management of comorbidities and timely identification of patients who may benefit from biologics. HIGHLIGHTS BOX What is already known about this topic? Mepolizumab, an anti-IL-5 monoclonal antibody, has been shown to induce clinical remission after 12 months of treatment. However, long-term evidence remains limited. What does this article add to our knowledge? The REMI-M study investigated the effectiveness of mepolizumab in achieving clinical and sustained remission over 24 months. How does this study impact current management guidelines? Mepolizumab can elicit long-term clinical and sustained remission in a conspicuous proportion of patients with severe eosinophilic asthma, supporting its role as a possible disease-modifying agent. Management of comorbidities and timely identification of patients who may benefit from biological treatment are crucial for optimizing long-term outcomes.

Impact of anti-eosinophilic biologic strategies on bronchial hyperreactivity in severe asthma

Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Biologics in severe eosinophilic asthma treatment: four years of a single-centre follow-up

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

A comparison of the impact of anti-IL5/5R therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting

Real world effectiveness of benralizumab on respiratory function and asthma control

Bronchiectasis in severe asthma: clinical and inflammatory response to biologic therapy.

The Effects of Benralizumab on Lung Volumes and Airway Resistance in Severe Eosinophilic Asthma: A Real-World Study

Asthma Exacerbation Profile on open label treatment with Benralizumab for severe eosinophilic asthma

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis

Effect of benralizumab on airway mucus, air-trapping and airway volume, assessed by functional respiratory imaging in severe eosinophilic asthma

Blood eosinophil subtype distribution following treatment with mepolizumab in patients with severe eosinophilic asthma

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series

Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience

Efficacy of Benralizumab in Patients with the Persistent Pattern

Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients

Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis